09 Apr 2026
· Regulatory information
Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announces that Nasdaq has informed the Company that it currently does not fulfil the ongoing listing requirement regarding active operations. In accordance with applicable rules, Nasdaq may therefore delist the Company’s financial instruments on 17 June 2026, provided that the Company has not, prior thereto, communicated concrete measures for how the operational requirement will be fulfilled or, in the event that the Company intends to carry out such far reaching changes that require a new listing review, submitted a complete listing application.
Read more
31 Mar 2026
Guard Therapeutics provides update on strategic review
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides an update regarding the strategic review that was announced in December 2025.
Read more
05 Feb 2026
· Regulatory information
Guard Therapeutics Announces Changes to the Company’s Management Team
Guard Therapeutics (publ) today announces changes to the company’s management team, in light of the conclusion of the clinical program for the drug candidate RMC-035 and the ongoing strategic review focused on a merger or a reverse takeover (RTO).
Read more
05 Feb 2026
Guard Therapeutics Provides Status Update Regarding Ongoing Strategic Review
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides a status update regarding the strategic review that the Company announced through a press release on 4 December 2025. The review, which includes an exploration of potential strategic alternatives, including the identification of potential counterparties for a merger or a reverse takeover (RTO), is progressing according to plan and is expected to be completed during the first quarter of 2026.
Read more
15 Jan 2026
Guard Therapeutics Partners in EU Consortium For Alport Syndrome
Guard Therapeutics (publ) today announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research Alliance (ERDERA), aimed at accelerating the development of therapies for rare kidney diseases.
Read more
16 Dec 2025
· Regulatory information
Guard Therapeutics presents the Nomination Committee for 2026
Guard Therapeutics International AB (publ) today announces that a Nomination Committee has been appointed in accordance with previous AGM resolutions.
Read more
08 Dec 2025
Guard Therapeutics appoints Redeye as financial advisor in the strategic review
Guard Therapeutics (publ) (“Guard” or the “Company”) announces today that Redeye Aktiebolag (“Redeye”) has been appointed as financial advisor in connection with the strategic review announced by the Company in its press release dated 4 December 2025. The review includes an assessment of potential strategic alternatives, including the identification of possible counterparties for a merger or a reverse acquisition.
Read more
05 Dec 2025
· Regulatory information
Guard Therapeutics changes Certified Adviser to Redeye AB
Guard Therapeutics (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will assume the role of Certified Adviser on 8 December 2025.
Read more
04 Dec 2025
· Regulatory information
Guard Therapeutics Explores Strategic Alternatives
Guard Therapeutics (publ) (“Guard” or the “Company”) today announces that the Board of Directors has resolved to commence an exploratory process regarding strategic alternatives, including identifying potential candidates for a merger or reverse takeover (RTO) of the Company. Guard believes that its listing on Nasdaq First North Growth Market in Stockholm, together with its cash position, may represent significant value for potential counterparties.
Read more
04 Dec 2025
Guard Therapeutics Provides Assessment of Full POINTER Study Results
Guard Therapeutics (public) (“Guard” or “the Company”) today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery. As previously communicated, the study did not meet its primary or key secondary efficacy endpoints, although promising signals were observed with the 30 mg dose level, particularly in reducing acute kidney injury. Given the overall negative outcome of the study, the Company has decided to discontinue all further development of RMC-035.
Read more